Skip to main content

Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.

Conferences
Azad, A; Iguchi, T; Alekseev, B; Shore, ND; Sugg, J; Haas, GP; Wozniak, M; O'Brien, T; Laird, D; Stenzl, A; Armstrong, AJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 1, 2022

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

June 1, 2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Azad, Arun, Taro Iguchi, Boris Alekseev, Neal D. Shore, Jennifer Sugg, Gabriel P. Haas, Michele Wozniak, et al. “Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

June 1, 2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis